Decheng Capital Management IV (Cayman), LLC — SEC Form 4 filings
SEC reporting owner CIK 1843384. 3 Form 4 filings on record with FilingPulse; latest filed 2025-02-19.
Transaction summary — filings shown
Covers all 3 filings on record, filed 2024-01-31 to 2025-02-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 3 filings — 2,050,000 shares, $35,200,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
- Largest priced transaction: purchase of 625,000 shares @ $16.00 ($10,000,000) in Aardvark Therapeutics, Inc., filed 2025-02-19.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | 10% owner | 1 | 2 legs · 1,250,000 sh · $20,000,000 | — | 4 |
| CG Oncology, Inc. (CGON) | 10% owner | 2 | 2 legs · 800,000 sh · $15,200,000 | — | 4 |
Form 4 filings — Decheng Capital Management IV (Cayman), LLC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-02-19 | 4 | Aardvark Therapeutics, Inc. (AARD) jointly with Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC, Cui Xiangmin | Conversion (C): 2,333,887 · Conversion (C): 333,412 · Purchase (P): 625,000 @ $16 · Purchase (P): 625,000 @ $16 · Conversion (C): 19,777,363 (derivative) @ $0 · Conversion (C): 2,825,337 (derivative) @ $0 | EDGAR |
| 2024-04-09 | 4/A | CG Oncology, Inc. (CGON) jointly with Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC, Cui Xiangmin | Purchase (P): 400,000 @ $19 | EDGAR |
| 2024-01-31 | 4 | CG Oncology, Inc. (CGON) jointly with Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC, Cui Xiangmin | Conversion (C): 3,628,198 · Purchase (P): 400,000 @ $19 · Conversion (C): 8,644,891 (derivative) · Conversion (C): 21,547,685 (derivative) · Conversion (C): 4,402,320 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1843384 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →